Nanobiotix

176 articles with Nanobiotix

• Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023

  3/14/2023

  NANOBIOTIX announces that it will provide an operational update and report its financial results for full-year ending December 31, 2022, on Tuesday, March 28, 2023, after the close of the US market.

• NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

  12/27/2022

  NANOBIOTIX announced the first patient in the United States has been randomized in NANORAY-312, a global Phase 3 registrational trial evaluating NBTXR3 for the treatment of elderly patients with locally advanced head and neck squamous cell carcinoma who are ineligible for platinum-based chemotherapy.

• NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement

  12/21/2022

  NANOBIOTIX, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced that it has ended the liquidity contract signed on October 23, 2012 with Gilbert Dupont.

• Voting Rights and Shares Capital of the Company - December 08, 2022

  12/8/2022

  The total number of exercisable at a Shareholders’ Meeting voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company.

• NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference

  11/15/2022

  NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a virtual fireside chat at the 5th annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022, at 9:15 AM ET / 3:15 PM CET.

• NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer

  11/14/2022

  NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’) today announced completion of the dose escalation part of a phase 1 dose escalation and dose expansion study evaluating potential first-in-class radioenhancer NBTXR3 for patients with locally advanced (LA) or borderline resectable (BR) pancreatic cancer (PC).

• NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer

  11/10/2022

  NANOBIOTIX, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced updated data from the Company’s phase 1 immunotherapy study, Study 1100.

• NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update

  11/9/2022

  NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and announced operational progress and cash position (unaudited) for the third quarter of 2022.

• NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3

  11/2/2022

  NANOBIOTIX announced the appointment of twelve global medical experts to a Scientific Advisory Board designed to support the Company regarding development of lead therapeutic candidate NBTXR3.

• NANOBIOTIX to Present at the Jefferies London Healthcare Conference

  10/31/2022

  NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a fireside chat at the Jefferies London Healthcare Conference.

• NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022

  10/27/2022

  NANOBIOTIX announced that it will report its financial results for the third quarter ended September 30, 2022, on Wednesday, November 9, 2022, after the close of the US market.

• NANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment Bank

  10/18/2022

  NANOBIOTIX announced execution of a final agreement with the European Investment Bank to re-align approximately €30.7 million in outstanding debt obligations with the Company’s expected development and commercialization timelines.

• Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022

  9/28/2022

  NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, provided an update on operational progress and announced its half year financial results for the six-month period ended June 30, 2022.

• Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022

  9/22/2022

  NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will report its financial results for half-year ending June 30, 2022, on Wednesday, September 28, 2022, after the close of the US market.

• Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

  9/21/2022

  NANOBIOTIX today announced determination of the recommended phase 2 dose (RP2D) of NBTXR3 in combination with pembrolizumab or nivolumab for the treatment of patients suffering from inoperable locoregional recurrent (LRR) or recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) that is resistant to prior immunotherapy.

• Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024

  9/12/2022

  NANOBIOTIX announced reaching an agreement in principle to restructure €30.7 million in outstanding debt obligations related to the Company’s 2018 loan agreement with the European Investment Bank.

• NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

  9/7/2022

  NANOBIOTIX (Euronext: NANO – Nasdaq: NBTX), and LianBio (Nasdaq: LIAN), today announced randomization of the first patient in Asia in NANORAY-312, a global Phase 3 registrational trial evaluating NBTXR3 for the treatment of elderly patients with locally advanced head and neck squamous cell carcinoma (“LA-HNSCC”) who are ineligible for platinum-based chemotherapy.

• NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life Sciences

  9/6/2022

  NANOBIOTIX announced that Laurent Levy, Co-Founder and Chief Executive Officer of Nanobiotix, has been named to the PharmaVoice 100 list of the most inspiring people in the life sciences.

• Nanobiotix to Present During the H.C. Wainwright Global Investment Conference in September 2022

  8/31/2022

  NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in the H.C. Wainwright 24th Annual Global Investment Conference to take place in-person in New York and virtually September 12th-14th 2022.

• Half-year Report on the Nanobiotix Liquidity Contract With Gilbert Dupont

  7/13/2022

  NANOBIOTIX, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, issued the Half-Year report on its liquidity contract with Gilbert Dupont.